Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsPaul Ponath, Shixin Qin, Douglas Ringler, Walter Newman, Charles Mackay
Estimating the term…
The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.
1-41. (canceled)
An isolated human eotaxin or fragment of said human eotaxin, wherein said human eotaxin has an amino acid sequence which shares at least 90% amino acid sequence similarity with amino acids 24-97 of SEQ ID NO:4, and wherein said human eotaxin or fragment can attract eosinophils and/or induce eosinophil accumulation, without substantially attracting or inducing accumulation of neutrophils or monocytes.
Isolated human eotaxin or a fragment thereof, said human eotaxin having an amino acid sequence encoded by a nucleic acid having the sequence of SEQ ID NO:
An essentially pure eotaxin polypeptide comprising the amino acid sequence set out in SEQ ID NO:2, wherein said polypeptide has eosinophil-specific chemoattractant activity.
An essentially pure eotaxin polypeptide, wherein said polypeptide:
Dependencies are inferred from the claim text.